Search

everythinglearnresearchcommunity

for

Search:↓

Trichoscopy is useful for diagnosing and monitoring systemic lupus erythematosus, with certain hair and scalp changes indicating more active disease.

Belimumab effectively controls SLE disease activity and reduces steroid use.

Skin problems are common in lupus patients and should be treated early to prevent worsening.

Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Chinese patients with systemic lupus erythematosus commonly experience oral ulcers, arthritis, alopecia, skin rash, and nephritis.

Certain skin symptoms can help detect and manage systemic lupus.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

The document concludes that various findings in rheumatology offer insights into disease severity, treatment responses, and potential risks in medication, with some limitations due to unspecified participant numbers.

Selenium supplements can help improve symptoms and metabolic markers in lupus patients.

Early identification of lupus through skin signs and blood tests is crucial in India.

Hydroxychloroquine may help COVID-19 patients with lupus.

Patients with lupus nephritis and COVID-19 can improve with proper treatment.

A TNFAIP3 gene mutation can cause unusual and varied symptoms of lupus and Sjogren's syndrome.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

42% of SLE patients had thyroid issues, mostly hypothyroidism.

Anifrolumab improves quality of life and reduces steroid use in lupus patients.

Early recognition and treatment of SLE can improve outcomes in patients with complex symptoms.

Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

Non-scarring hair loss is common in lupus patients and can be diagnosed with specific hair and tissue tests.

Higher disease activity in systemic lupus erythematosus is strongly linked to more internal organ damage.

Tjalma Syndrome is a rare condition in people with lupus, causing fluid buildup and high CA-125 levels, but not due to tumors.

Hair loss in SLE patients is mostly due to chronic telogen effluvium and is linked to moderate disease activity.

Tph cells are linked to the severity of systemic lupus erythematosus.

CLASI is a valid tool for assessing skin activity and damage in lupus patients.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Psychosis can be an early sign of neuropsychiatric lupus, treatable with tailored medication.